JP2017158567A - 抗ssx−2 t細胞受容体及び関連材料並びに使用方法 - Google Patents
抗ssx−2 t細胞受容体及び関連材料並びに使用方法 Download PDFInfo
- Publication number
- JP2017158567A JP2017158567A JP2017082965A JP2017082965A JP2017158567A JP 2017158567 A JP2017158567 A JP 2017158567A JP 2017082965 A JP2017082965 A JP 2017082965A JP 2017082965 A JP2017082965 A JP 2017082965A JP 2017158567 A JP2017158567 A JP 2017158567A
- Authority
- JP
- Japan
- Prior art keywords
- tcr
- ssx
- seq
- cancer
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Mycology (AREA)
- Physics & Mathematics (AREA)
Abstract
【解決手段】滑膜肉腫Xブレイクポイント(SSX)−2に対し抗原特異性を有する、単離又は精製されたT細胞受容体(TCR)、関連ポリペプチド及びタンパク質、並びに関連核酸、組換え発現ベクター、ホスト細胞、及び細胞集団。該TCRに関連する、抗体又はその抗原結合部位、及び医薬組成物。ホストにおける癌の存在を検出する方法、及びホストにおける癌を治療する又は予防する方法。
【選択図】なし
Description
本特許出願は、参照によって組み込まれる、2010年9月21日出願の米国仮特許出願第61/384,931号の利益を主張する。
同時に添えて提出した、コンピュータで読み取ることのできるヌクレオチド/アミノ酸配列リストは、その全体が参照により本明細書に組み込まれるものであり、以下のように特定される:2011年8月22日付けの「708841ST25.TXT」と名付けられた1つの41,480バイトのASCII(テキスト)ファイル。
本発明は、滑膜肉腫Xブレイクポイント(SSX)−2(HOM−MEL−40としても知られている)に対する抗原特異性を有する、単離又は精製されたT細胞受容体(TCR)を提供する。SSX−2は、SSX−1、SSX−3、SSX−4、SSX−5、SSX−6、SSX−7、SSX−8、SSX−9、及びSSX−10をも含む、10の相同性の高い核タンパク質のSSXファミリーのメンバーである。SSXタンパク質は、腫瘍細胞及び精巣のMHCを発現しない生殖細胞でのみ発現する癌精巣抗原(CTA)である。SSX−2は、メラノーマ、頭部癌、頸部癌、リンパ腫、多発性骨髄腫、膵臓癌、前立腺癌、肉腫、肝細胞及び結腸癌を含む種々のヒトの癌で発現するが、これらに限定されない。SSX−2タンパク質は、配列番号1を含み得る、配列番号1からなり得る、又は本質的に配列番号1からなり得る。
本実施例は、SSX−2を発現するためのレトロウイルスベクターの作製を説明し、特定の細胞株におけるSSX−2の発現を示す。
SSX−2は938mel、U251、T567A、SKMEL23、及びSKMEL37細胞においても測定された。β−アクチンに対して基準化したSSX−2のコピー数を表1に示す。
本実施例は、SSX−2特異的TCRを発現するためのレトロウイルスベクターの作製を説明する。
本実施例は、SSX−2 TCRを用いて操作したPBLが、SSX−2ペプチド特異的反応性及びテトラマー結合を示すことを明らかにする。
本実施例は、実施例2のSSX−2 TCRを用いて操作したPBLが腫瘍細胞株に対して反応性を示すことを明らかにする。
本実施例は、SSX−2 TCRで操作したPBLが、他のSSXタンパク質ペプチドに対し反応性を示すことを明らかにする。
本実施例は、コドン最適化及びマウス定常領域の導入が、ヒトPBLにおいてSSX−2 TCRの発現及び機能を改善したことを明らかにする。
本実施例は、SSX−2 TCR、コドン最適化SSX−2 TCR、又はコドン最適化ヒト−マウスキメラSSX−2 TCRを用いて操作したPBLが、腫瘍細胞株に対して反応性を示すことを明らかにする。
本実施例は、SSX−2 TCR、コドン最適化SSX−2 TCR、又はコドン最適化ヒト−マウスキメラSSX−2 TCRを用いて操作したPBLが、SSX2+/HLA−A2+標的細胞との共培養の際に増殖することを明らかにする。
本実施例は、SSX−2 TCR、コドン最適化SSX−2 TCR、又はコドン最適化ヒト−マウスキメラSSX−2 TCRを用いて操作したPBLが、SSX−2+/HLA−A2+標的細胞に対して特異的溶解活性を示すことを明らかにする。
本実施例は、SSX−2 TCR、コドン最適化SSX−2 TCR、又はコドン最適化ヒト−マウスキメラSSX−2 TCRを用いて操作したPBLが、ペプチドパルスしたT2細胞と共培養した際にサイトカインを分泌することを明らかにする。
本実施例は、脱メチル化剤、5−アザ−2’−デオキシシチジン(DAC)、がSSX2−TCRで操作したPBLによるmel1300細胞の認識を亢進することを明らかにする。
Claims (33)
- 滑膜肉腫Xブレイクポイント(SSX)−2(配列番号1)に対して抗原特異性を有する、単離又は精製されたT細胞受容体(TCR)。
- TCRが、SSX−3(配列番号3)、SSX−4(配列番号4)、SSX−5(配列番号5)、SSX−9(配列番号6)、及びSSX−10 (配列番号7)のいずれか1以上も認識する、請求項1に記載のTCR。
- TCRが、KASEKIFYV(配列番号2)を含むSSX−2ペプチドに対して抗原特異性を有する、請求項1又は2に記載のTCR。
- TCRが、KVSEKIVYV(配列番号8)、KSSEKIVYV(配列番号9)、KASEKIIYV(配列番号10)、KSSEKIIYV(配列番号11)、及びKASEKILYV(配列番号12)のいずれか1以上を認識する、請求項1〜3のいずれか1項に記載のTCR。
- TCRが、配列番号13〜18を含むアミノ酸配列を含む、請求項1〜4のいずれか1項に記載のTCR。
- TCRが配列番号19及び20を含む、請求項1〜5のいずれか1項に記載のTCR。
- TCRが配列番号21及び22をさらに含む、請求項6に記載のTCR。
- TCRが:
a)配列番号23及び24、又は
b)配列番号25及び26
を含む、請求項1〜7のいずれか1項に記載のTCR。 - 請求項1〜8のいずれか1項に記載のTCRの機能的部分を含む単離又は精製されたポリペプチドであって、該機能的部分が配列番号13〜18のアミノ酸配列を含む、ポリペプチド。
- 該部分が配列番号19及び20のアミノ酸配列を含む、請求項9に記載の単離又は精製されたポリペプチド。
- a)配列番号23及び24;又は
b)配列番号25及び26
を含む、請求項10に記載の単離又は精製されたポリペプチド。 - 請求項9〜11のいずれか1項に記載のポリペプチドの少なくとも1つを含む、単離又は精製されたタンパク質。
- 配列番号19を含む第一のポリペプチド鎖及び配列番号20を含む第二のポリペプチド鎖を含む、請求項12に記載の単離又は精製されたタンパク質。
- a)配列番号23を含む第一のポリペプチド鎖及び配列番号24を含む第二のポリペプチド鎖;又は
b)配列番号25を含む第一のポリペプチド鎖及び配列番号26を含む第二のポリペプチド鎖
を含む、請求項13に記載の単離又は精製されたタンパク質。 - タンパク質が融合タンパク質である、請求項12〜14のいずれか1項に記載の単離又は精製されたタンパク質。
- タンパク質が組換え抗体である、請求項12〜15のいずれか1項に記載の単離又は精製されたタンパク質。
- 請求項1〜8のいずれか1項に記載のTCR、請求項9〜11のいずれか1項に記載のポリペプチド、又は請求項12〜16のいずれか1項に記載のタンパク質をコードするヌクレオチド配列を含む、単離又は精製された核酸。
- 核酸が配列番号27〜30のいずれか1つを含むヌクレオチド配列を含む、請求項17に記載の核酸。
- 請求項17又は18に記載の核酸のヌクレオチド配列に相補的なヌクレオチド配列を含む、単離又は精製された核酸。
- 請求項17又は18に記載の核酸のヌクレオチド配列にストリンジェントな条件でハイブリダイズするヌクレオチド配列を含む、単離又は精製された核酸。
- 請求項17〜20のいずれか1項に記載の核酸を含む、組換え発現ベクター。
- ベクターがレトロウイルスベクターである、請求項21に記載の組換え発現ベクター。
- 請求項21又は22に記載の組換え発現ベクターを含む、単離されたホスト細胞。
- 細胞が末梢血リンパ球(PBL)である、請求項23に記載の単離されたホスト細胞。
- PBLがCD8+ T細胞又はCD4+ T細胞である、請求項24に記載の単離されたホスト細胞。
- 請求項23〜25のいずれか1項に記載の少なくとも1つのホスト細胞を含む細胞集団。
- 請求項1〜8のいずれか1項に記載のTCRの機能的部分に特異的に結合する、抗体又はその抗原結合部位であって、該機能的部分が配列番号13〜18のアミノ酸配列を含む、抗体又はその抗原結合部位。
- 請求項1〜8のいずれか1項に記載のTCR、請求項9〜11のいずれか1項に記載のポリペプチド、請求項12〜16のいずれか1項に記載のタンパク質、請求項17〜20のいずれか1項に記載の核酸、請求項21若しくは22に記載の組換え発現ベクター、請求項23〜25のいずれか1項に記載のホスト細胞、請求項26に記載の細胞集団、又は請求項27に記載の抗体若しくはその抗原結合部位、及び医薬上許容される担体を含む、医薬組成物。
- (a)癌細胞を含むサンプルを、請求項1〜8のいずれか1項に記載のTCR、請求項9〜11のいずれか1項に記載のポリペプチド、請求項12〜16のいずれか1項に記載のタンパク質、請求項17〜20のいずれか1項に記載の核酸、請求項21若しくは22に記載の組換え発現ベクター、請求項23〜25のいずれか1項に記載のホスト細胞、請求項26に記載の細胞集団、又は請求項27に記載の抗体若しくはその抗原結合部位と接触させ、それにより複合体を形成させること、及び
(b)該複合体を検出すること、
を含む、癌の存在を検出する方法であって、該複合体の検出が癌の存在の指標となる、方法。 - 請求項1〜8のいずれか1項に記載のTCR、請求項9〜11のいずれか1項に記載のポリペプチド、請求項12〜16のいずれか1項に記載のタンパク質、請求項17〜20のいずれか1項に記載の核酸、請求項21若しくは22に記載の組換え発現ベクター、請求項23〜25のいずれか1項に記載のホスト細胞、請求項26に記載の細胞集団、又は請求項27に記載の抗体若しくはその抗原結合部位を含む、哺乳動物における癌を治療する又は予防するための医薬組成物。
- 癌が、頭頸部癌、卵巣癌、肺癌、神経膠腫、メラノーマ、腎臓癌、リンパ腫、結腸癌、膵臓癌、乳癌、前立腺癌、滑膜肉腫、骨肉腫、平滑筋肉腫子宮、及び肝細胞癌からなる群より選択される、請求項29に記載の方法又は請求項30に記載の医薬組成物。
- ホスト細胞がホストの自己の細胞である、又は細胞集団がホストの自己の細胞である、請求項29若しくは31に記載の方法又は請求項30若しくは31に記載の医薬組成物。
- 5-アザ-2'-デオキシシチジン(DAC)をさらに含む、請求項30〜32のいずれか1項に記載の医薬組成物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38493110P | 2010-09-21 | 2010-09-21 | |
US61/384,931 | 2010-09-21 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013529285A Division JP6133209B2 (ja) | 2010-09-21 | 2011-09-14 | 抗ssx−2t細胞受容体及び関連材料並びに使用方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2017158567A true JP2017158567A (ja) | 2017-09-14 |
Family
ID=44720141
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013529285A Active JP6133209B2 (ja) | 2010-09-21 | 2011-09-14 | 抗ssx−2t細胞受容体及び関連材料並びに使用方法 |
JP2017082965A Pending JP2017158567A (ja) | 2010-09-21 | 2017-04-19 | 抗ssx−2 t細胞受容体及び関連材料並びに使用方法 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013529285A Active JP6133209B2 (ja) | 2010-09-21 | 2011-09-14 | 抗ssx−2t細胞受容体及び関連材料並びに使用方法 |
Country Status (10)
Country | Link |
---|---|
US (3) | US9345748B2 (ja) |
EP (2) | EP3533802B1 (ja) |
JP (2) | JP6133209B2 (ja) |
CN (1) | CN103124740B (ja) |
AU (1) | AU2011305817B2 (ja) |
CA (1) | CA2811788C (ja) |
ES (2) | ES2876176T3 (ja) |
IL (3) | IL225063A (ja) |
PT (2) | PT2619223T (ja) |
WO (1) | WO2012040012A1 (ja) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012040012A1 (en) * | 2010-09-21 | 2012-03-29 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-ssx-2 t cell receptors and related materials and methods of use |
CN104870011A (zh) | 2011-11-03 | 2015-08-26 | 托莱拉医疗股份有限公司 | 选择性抑制t细胞应答的抗体和方法 |
US20130273089A1 (en) | 2011-11-03 | 2013-10-17 | Tolera Therapeutics, Inc. | Antibody and methods for selective inhibition of t-cell responses |
US10316289B2 (en) | 2012-09-06 | 2019-06-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of producing T memory stem cell populations |
ES2745472T3 (es) * | 2013-07-15 | 2020-03-02 | The U S A As Represented By The Secretary Department Of Health And Human Services Office Of Tech Tra | Receptores de células T anti-virus del papiloma humano 16 E6 |
JP6580579B2 (ja) * | 2014-01-29 | 2019-09-25 | ユニバーシティー ヘルス ネットワーク | T細胞受容体を発現する細胞を生産する方法および組成物 |
CA2955984A1 (en) | 2014-07-22 | 2016-01-28 | The University Of Notre Dame Du Lac | Molecular constructs and uses thereof |
JP2017534280A (ja) * | 2014-10-31 | 2017-11-24 | ベイラー カレッジ オブ メディスンBaylor College Of Medicine | 腫瘍を標的にするがt細胞を標的にしないサバイビン特異的t細胞受容体 |
AU2015338984A1 (en) * | 2014-10-31 | 2017-04-27 | The Trustees Of The University Of Pennsylvania | Methods and compositions for modified T cells |
US11098283B2 (en) | 2015-08-25 | 2021-08-24 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cells modified to overexpress c-Myb |
WO2017070042A1 (en) | 2015-10-20 | 2017-04-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of producing t cell populations using akt inhibitors |
WO2017139199A1 (en) | 2016-02-10 | 2017-08-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Inducible arginase |
EP3448882B1 (en) | 2016-04-26 | 2021-11-24 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Anti-kk-lc-1 t cell receptors |
CA3037882A1 (en) | 2016-09-23 | 2018-03-29 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of preparing an isolated population of dendritic cells and methods of treating cancer using same |
US20200080057A1 (en) | 2016-12-13 | 2020-03-12 | The United States Of America,As Represented By The Secretary,Department Of Health And Human Services | Methods of preparing an isolated or purified population of thymic emigrant cells and methods of treatment using same |
EP3579870A4 (en) | 2017-02-07 | 2020-12-30 | Seattle Children's Hospital (DBA Seattle Children's Research Institute) | PHOSPHOLIPID ETHER (PLE) T CAR-LYMPHOCYTE TUMOR (CTCT) TARGETING AGENTS |
EP3579877A4 (en) * | 2017-02-09 | 2020-12-09 | The Regents of The University of California | CHEMERIC T-LYMPHOCYTE ANTIGENIC RECEPTORS AND METHODS OF USE |
JP7178355B2 (ja) | 2017-02-28 | 2022-11-25 | エンドサイト・インコーポレイテッド | Car t細胞療法のための組成物および方法 |
AU2018235130B2 (en) | 2017-03-15 | 2023-12-07 | Oxford Biomedica (Uk) Limited | Method |
WO2018226741A1 (en) | 2017-06-05 | 2018-12-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T-cells modified to overexpress phf19 |
EP3692140B1 (en) | 2017-10-05 | 2023-07-19 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Methods for selectively expanding cells expressing a tcr with a murine constant region |
JP2021500875A (ja) | 2017-10-06 | 2021-01-14 | オスロ ウニヴェルスィテーツスィーケフース ハーエフOslo Universitetssykehus Hf | キメラ抗原受容体 |
US20200316122A1 (en) | 2017-10-11 | 2020-10-08 | The United States Of America,As Represented By The Secretary,Department Of Health And Human Services | Methods of producing t cell populations using p38 mapk inhibitors |
US11466071B2 (en) * | 2017-12-04 | 2022-10-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | HLA class I-restricted t cell receptors against mutated RAS |
CA3089051A1 (en) | 2018-01-22 | 2019-07-25 | Endocyte, Inc. | Methods of use for car t cells |
EP3749770A1 (en) | 2018-02-09 | 2020-12-16 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Tethered interleukin-15 and interleukin-21 |
WO2019204683A1 (en) * | 2018-04-19 | 2019-10-24 | Board Of Regents, The University Of Texas System | T cell receptors with mage-b2 specificity and uses thereof |
EP3784774A1 (en) | 2018-04-24 | 2021-03-03 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Methods of producing t cell populations using hydroxycitric acid and/or a salt thereof |
US20220403001A1 (en) | 2018-06-12 | 2022-12-22 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
CN110950949B (zh) * | 2018-09-26 | 2022-04-05 | 香雪生命科学技术(广东)有限公司 | 一种识别ssx2抗原的t细胞受体 |
AU2020298326A1 (en) * | 2019-06-21 | 2022-01-27 | Children's National Medical Center | Methods and composition for a binding molecule targeting cancer cells expressing SSX2 peptide 41-49 in HLA-A*0201 context |
US11642409B2 (en) | 2019-06-26 | 2023-05-09 | Massachusetts Insttute of Technology | Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof |
WO2021016887A1 (zh) * | 2019-07-30 | 2021-02-04 | 广东香雪精准医疗技术有限公司 | 识别ssx2抗原短肽的t细胞受体 |
CN112409474B (zh) * | 2019-08-23 | 2023-02-28 | 香雪生命科学技术(广东)有限公司 | 一种识别ssx2抗原的高亲和力tcr |
CN112442119B (zh) * | 2019-09-05 | 2023-02-24 | 香雪生命科学技术(广东)有限公司 | 一种识别ssx2的高亲和力t细胞受体 |
WO2021061648A1 (en) | 2019-09-23 | 2021-04-01 | Massachusetts Institute Of Technology | Methods and compositions for stimulation of endogenous t cell responses |
MX2022011080A (es) | 2020-03-10 | 2023-01-04 | Massachusetts Inst Technology | Metodos para generar celulas nk de tipo memoria modificadas y composiciones de las mismas. |
US20210338833A1 (en) | 2020-05-01 | 2021-11-04 | Massachusetts Institute Of Technology | Chimeric antigen receptor-targeting ligands and uses thereof |
WO2021221783A1 (en) | 2020-05-01 | 2021-11-04 | Massachusetts Institute Of Technology | Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof |
AU2021341969A1 (en) | 2020-09-08 | 2023-03-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell phenotypes associated with response to adoptive cell therapy |
US20240018210A1 (en) | 2020-11-13 | 2024-01-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic | Enhanced antigen reactivity of immune cells expressing a mutant non-signaling cd3 zeta chain |
CN115819555A (zh) * | 2021-09-17 | 2023-03-21 | 香雪生命科学技术(广东)有限公司 | 一种识别ssx2的高亲和力tcr |
WO2023130040A2 (en) | 2021-12-31 | 2023-07-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell therapy with vaccination as a combination immunotherapy against cancer |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6133209B2 (ja) * | 2010-09-21 | 2017-05-24 | アメリカ合衆国 | 抗ssx−2t細胞受容体及び関連材料並びに使用方法 |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4450150A (en) | 1973-05-17 | 1984-05-22 | Arthur D. Little, Inc. | Biodegradable, implantable drug delivery depots, and method for preparing and using the same |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
IN165717B (ja) | 1986-08-07 | 1989-12-23 | Battelle Memorial Institute | |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
DK0546073T3 (da) | 1990-08-29 | 1998-02-02 | Genpharm Int | Frembringelse og anvendelse af transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
JP3266311B2 (ja) | 1991-05-02 | 2002-03-18 | 生化学工業株式会社 | 新規ポリペプチドおよびこれを用いる抗hiv剤 |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
CA2398136A1 (en) | 2000-02-08 | 2001-08-16 | The Penn State Research Foundation | Immunotherapy using interleukin 13 receptor subunit alpha 2 |
EP1227321A1 (en) | 2000-12-28 | 2002-07-31 | Institut für Bioanalytik GmbH | Reversible MHC multimer staining for functional purification of antigen-specific T cells |
US20040180354A1 (en) * | 2002-09-06 | 2004-09-16 | Simard John J.L. | Epitope sequences |
CA2523798A1 (en) * | 2003-04-29 | 2004-11-11 | Wyeth | Methods for prognosis and treatment of solid tumors |
DE602004031116D1 (de) | 2003-07-22 | 2011-03-03 | Ludwig Inst For Cancer Res New York | Von hla-klasse-ii-molekülen präsentierte ssx-2-peptide |
AU2005265182B2 (en) | 2004-06-17 | 2012-06-21 | Mannkind Corporation | Epitope analogs |
CN101001868A (zh) * | 2004-06-17 | 2007-07-18 | 曼康公司 | 表位类似物 |
AU2006259307B2 (en) * | 2005-06-17 | 2012-12-20 | Mannkind Corporation | Epitope analogues |
CA2651174A1 (en) * | 2006-05-03 | 2007-11-15 | Government Of The United States Of America, Represented By The Secretary , Department Of Health And Human Services | Chimeric t cell receptors and related materials and methods of use |
WO2008039694A2 (en) * | 2006-09-26 | 2008-04-03 | St. Jude Children's Research Hospital | Methods and compositions for monitoring t cell receptor diversity |
US8785601B2 (en) * | 2009-01-28 | 2014-07-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors and related materials and methods of use |
-
2011
- 2011-09-14 WO PCT/US2011/051537 patent/WO2012040012A1/en active Application Filing
- 2011-09-14 PT PT11763819T patent/PT2619223T/pt unknown
- 2011-09-14 US US13/820,802 patent/US9345748B2/en active Active
- 2011-09-14 JP JP2013529285A patent/JP6133209B2/ja active Active
- 2011-09-14 EP EP19166061.2A patent/EP3533802B1/en active Active
- 2011-09-14 ES ES19166061T patent/ES2876176T3/es active Active
- 2011-09-14 CA CA2811788A patent/CA2811788C/en active Active
- 2011-09-14 EP EP11763819.7A patent/EP2619223B1/en active Active
- 2011-09-14 ES ES11763819T patent/ES2734889T3/es active Active
- 2011-09-14 CN CN201180045492.0A patent/CN103124740B/zh active Active
- 2011-09-14 PT PT191660612T patent/PT3533802T/pt unknown
- 2011-09-14 AU AU2011305817A patent/AU2011305817B2/en active Active
-
2013
- 2013-03-05 IL IL225063A patent/IL225063A/en active IP Right Grant
-
2016
- 2016-04-19 US US15/132,863 patent/US10143724B2/en active Active
-
2017
- 2017-04-19 JP JP2017082965A patent/JP2017158567A/ja active Pending
- 2017-09-13 IL IL254469A patent/IL254469B/en active IP Right Grant
-
2018
- 2018-10-29 US US16/173,701 patent/US10864252B2/en active Active
-
2019
- 2019-11-28 IL IL271021A patent/IL271021B/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6133209B2 (ja) * | 2010-09-21 | 2017-05-24 | アメリカ合衆国 | 抗ssx−2t細胞受容体及び関連材料並びに使用方法 |
Also Published As
Publication number | Publication date |
---|---|
IL271021B (en) | 2021-12-01 |
US20190054143A1 (en) | 2019-02-21 |
IL225063A (en) | 2017-09-28 |
PT3533802T (pt) | 2021-06-21 |
IL254469A0 (en) | 2017-11-30 |
CN103124740A (zh) | 2013-05-29 |
WO2012040012A1 (en) | 2012-03-29 |
US20130274203A1 (en) | 2013-10-17 |
EP2619223A1 (en) | 2013-07-31 |
AU2011305817A1 (en) | 2013-04-04 |
US20160279196A1 (en) | 2016-09-29 |
PT2619223T (pt) | 2019-07-11 |
IL254469B (en) | 2019-12-31 |
US10143724B2 (en) | 2018-12-04 |
CN103124740B (zh) | 2015-09-02 |
JP2014500002A (ja) | 2014-01-09 |
CA2811788C (en) | 2020-12-29 |
US9345748B2 (en) | 2016-05-24 |
CA2811788A1 (en) | 2012-03-29 |
EP3533802B1 (en) | 2021-03-17 |
AU2011305817B2 (en) | 2014-12-11 |
ES2876176T3 (es) | 2021-11-12 |
JP6133209B2 (ja) | 2017-05-24 |
ES2734889T3 (es) | 2019-12-12 |
US10864252B2 (en) | 2020-12-15 |
EP3533802A1 (en) | 2019-09-04 |
EP2619223B1 (en) | 2019-04-10 |
IL271021A (en) | 2020-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6133209B2 (ja) | 抗ssx−2t細胞受容体及び関連材料並びに使用方法 | |
JP6855426B2 (ja) | Hla−a1−又はhla−cw7−拘束性mageを認識するt細胞受容体 | |
US11434272B2 (en) | Anti-human papillomavirus 16 E7 T cell receptors | |
JP7270001B2 (ja) | Mhcクラスii拘束性mage-a3を認識するt細胞受容体 | |
JP6643394B2 (ja) | M971キメラ抗原受容体 | |
JP6628719B2 (ja) | 抗ヒトパピローマウイルス16 e6 t細胞受容体 | |
US7820174B2 (en) | T cell receptors and related materials and methods of use | |
JP6943568B2 (ja) | 胸腺間質性リンパ球新生因子受容体特異的キメラ抗原受容体及びそれを使用する方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170421 |
|
RD01 | Notification of change of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7426 Effective date: 20170526 |
|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20170526 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20170526 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170622 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180227 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180528 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A132 Effective date: 20180911 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181211 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190205 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190502 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20191008 |